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Specific Aim 2
Specific Aim 2 proposed to apply differential expression analyses to detect aberrant transcripts associated with cancer stage and subtype. During the 2011 award period the P.I. developing software to construct gene expression matrices from many samples and verified that ER/PR and ERBB2 were outliers in mutually exclusive sample subsets. Additionally, the P.I. evaluated several publicly available software packages including DESeq (http://www-huber. embl [7, 8] . We determined that DESeq was most robust for determining gene-level differential expression events and will be using this tool in subsequent analyses. Transcripts that are highly expressed in a minority of cancer tissues may not be detectable by standard differential expression analysis but could represent novel cancer subtypes. These transcripts are often known as "outliers" because they only appear in a subset of the samples in a given cohort. Outlier detection algorithms have been used successfully to detect aberrant transcripts in prostate cancer, including the TMPRSS2-ERG gene fusion; however, these algorithms were designed for microarray gene expression data and not RNA-Seq [9] . Accordingly, the P.I. has designed, implemented, and tested a preliminary version of an RNA-Seq outlier analysis algorithm on breast cancer tissue data. The P.I. plans to publish this algorithm as an R package and submit a manuscript to a bioinformatics journal during the award period. Intriguingly, the algorithm nominated a set of five long RNA transcripts in cancer that did not appear in any normal tissues or cell lines (Figure 1) . One of these transcripts, named M41, was expressed across multiple tissues (Figure 3 ), suggesting that it may play a role in multiple cancer types.
In summary, the P.I. applied the novel transcript discovery pipeline to preliminary breast tumor RNASeq data and nominated five breast cancer outliers that are long non-coding RNAs (Figure 1) . Four of the five outliers were validated by qRT-PCR ( Figure 2 ). One of these long non-coding RNAs, termed M41 based on existing annotations, was highly expressed in breast, lung, and prostate cancer ( Figure 3 ). In 2012, the P.I. will continue working on the plan for Specific Aim 2, with the goal of submitting a manuscript on the outlier analysis algorithm. Many of the items in the work plan are still in progression, and the P.I. anticipates
The M41 lncRNA is highly expressed in breast, lung, and prostate cancer completing the majority of these tasks in 2012.
Specific Aim 3
Specific Aim 3 proposes to develop a method that detects associations between novel transcripts and known prognostic genes. During the 2011 award period the P.I. began developing and/or implementing existing software packages for clustering and correlating novel transcripts with known protein coding genes. This work is still preliminary and under development. The P.I. expects to make significant progress on this aim during the 2012 award period. Key research accomplishments
Summary of progress towards completion of work plan
• The P.I. developed and published a new software tool, ChimeraScan, which enables de novo detection of gene fusions in RNA-Seq data [1] . The manuscript describes the fusion detection methodology in detail and has been included the Appendices of this report. The ChimeraScan software is hosted online (http://chimerascan.googlecode.com) where it has been downloaded over 270 times by potential users. The P.I. continues to maintain and improve ChimeraScan and anticipates making additional software releases during the 2012-2013 award period.
• The P.I. has developed an infrastructure called Oncoseq for processing vast amounts of RNA-Seq data.
The Oncoseq software package is now being used to analyze the breast cancer transcriptomes for discovery of novel transcripts. The package itself is versatile and capable of analyzing RNA-Seq data for a variety of other projects as well. We are currently preparing a manuscript for publication in a bioinformatics journal.
• The Oncoseq infrastructure has been used to process 207 RNA-Seq libraries from breast cancer cell lines and tissues. The results of this analysis have been used in the discovery of novel classes of gene fusions in breast cancer, including NOTCH and MAST kinase gene fusions [2] . The manuscript discussing these findings has been included in the Appendices of this report.
Reportable outcomes
Toward the fulfillment of Specific Aim 1B, the P.I. developed a software package for de novo assembly of gene fusion breakpoints from paired-end RNA-Seq data. The tool, ChimeraScan [1] , is now publicly available at http://chimerascan.googlecode.com and published as an Application Note at the journal Bioinformatics (see article in Appendices). In addition, the P.I. applied ChimeraScan towards the discovery of gene fusions and was co-author on a recent publication that nominated the MAST and NOTCH kinases as recurrent families of genetic aberrations in triple negative breast cancer [2] (see article in Appendices).
During the grant period through March 2012, the P.I. has completed significant coursework, examinations, and research training ( Table 1 
Conclusions
In 2011, the P.I. made significant progress towards completion of the Specific Aims proposed. He was an author on two manuscripts that focused on breast cancer samples, presented at national scientific meetings, made significant progress towards finishing his Ph.D., and made several discoveries of intergenic lncRNAs differentially expressed in breast tumors. In the coming year, the P.I. will gain enormous insight into the transcriptomic complexity of breast cancer as he moves from primary data analysis towards interpretation, and leverages the unique RNA-Seq data set in order to examine patterns of gene expression across subtypes of breast cancer. The P.I. expects to make important contributions to the field by identifying novel gene fusions, mutations, and lncRNAs implicated in breast cancer progression.
INTRODUCTION
High-throughput transcriptome sequencing (RNA-Seq) facilitates detection of aberrant, chimeric RNAs (Maher et al., 2009a; Maher et al., 2009b) . Methods for chimera detection have already uncovered recurrent classes of clinically relevant gene fusions in prostate (Palanisamy et al., 2010) and lymphoid cancers (Steidl et al. 2011) . Therefore, the continued development of accurate and efficient software tools for chimera discovery is of major clinical significance. To this end, we have developed a chimera discovery methodology, or ChimeraScan, and offer it as open-source software package for the community to utilize for their own sequencing efforts. ChimeraScan includes features such as the ability to process long (>75 bp) paired-end reads, processing of ambiguously mapping reads, detection of reads spanning a fusion junction, integration with the popular Bowtie aligner (Langmead et al., 2009) , supports the standardized SAM format and generation of HTML reports for easy investigation of results. Overall, we believe that the ChimeraScan will facilitate the discovery of additional gene fusions that may serve as clinically relevant targets in cancer.
METHODS
Initial paired-end alignment: ChimeraScan uses Bowtie to align paired-end reads to a combined genome-transcriptome reference. An indexing program creates the combined index from genomic sequences (FASTA format) and transcript features (UCSC GenePred format). Paired alignments within the fragment size range (default: 0-1000) are referred to as concordantly mapping reads (Fig. 1A) . ChimeraScan uses these alignments to estimate the * To whom correspondence should be addressed. insert size distribution of the library, which will later be used to filter out likely false positive chimeras.
Trimmed paired-end alignment: read pairs that could not be aligned concordantly are trimmed into smaller segments (default = 25 bp) and realigned. Trimming increases the chance that neither read alignment spans a chimeric junction, thereby improving sensitivity for nominating chimeras.
Nomination of chimera candidates: the trimmed alignments are scanned for evidence of discordant read pairs, or reads that align to distinct references or distant genomic locations (as determined by the fragment size range) of the same reference. Reads aligning to overlapping transcripts are not considered discordant. ChimeraScan clusters the discordant reads and produces a list of putative 5 -3 transcript pairs that serve as chimera candidates.
Detection of reads spanning the chimeric junction: ChimeraScan builds a new reference index from the set of putative chimeric junction sequences, and realigns candidate junction-spanning reads to this index. Candidate spanning reads are either (i) discordant reads with trimmed alignments bordering a junction or (ii) unmapped reads whose mates align to a predicted chimera (Fig. 1B) . A read that spans a junction by more than a minimum 'anchor' length is denoted as a 'spanning' read. We compute the required 'anchor' length separately for each chimera by insisting that the number of bases overlapping its junction be greater than number of homologous bases between the 5 and 3 genes at the breakpoint plus the number of mismatches allowed.
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Filtering false-positive chimeras: after spanning reads are incorporated, ChimeraScan filters chimeras with few supporting reads (default is <3 reads) and chimeras with fragment sizes far outside the range of the distribution (default is >99% of all fragment sizes). When isoforms of the same gene support a fusion ChimeraScan only retains the isoform(s) with highest coverage.
Reporting chimeras: ChimeraScan produces a tabular text file describing each chimera, and optionally generates a user-friendly HTML page with links to detailed descriptions of the chimeric genes.
RESULTS
To evaluate the results from ChimeraScan, we applied it to three well-characterized cancer cell lines known to harbor multiple chimeric transcripts: VCaP (prostate cancer, 2×53 bp) , LNCaP (prostate cancer, 2×34 bp) and MCF7 (breast cancer, 2×35 bp) (Hampton et al., 2009; Volik et al., 2006) . Sequence data are deposited in GenBank under the accession number GSE29098. We aligned to human genome (VR-hg19) and UCSC known transcripts (December 2010), allowing for up to two mismatches and no >100 alignments per read. The trimmed alignment step was performed with 25 bp segments.
As our initial benchmark, we confirmed that ChimeraScan was able to recapitulate experimentally validated candidates, our 'gold standard' (Supplementary Table 1 (Maher et al., 2009b) , TBL1XR1-RGS17 was previously detected by a paired-end diTag approach and experimentally confirmed (Ruan et al., 2007) . Another novel candidate was the intrachromosomal rearrangement, NDUFAF2-MAST4, in VCaP that is supported by just two encompassing reads and one spanning reads. The ability to identify a high-quality spanning read that uniquely confirms the fusion junction (Supplementary Table 2 ), thereby increasing our confidence in NDUFAF2-MAST4, demonstrates the sensitivity of ChimeraScan.
We Table 5 ). While deFuse nominated the fewest chimeras, it only detected 60% of the true positives. In comparison, ChimeraScan detected 90% of the true positives from 78 predicted chimeras. Of the remaining programs, MapSplice nominated 400 chimeras while detecting 60% of the true positives and ShortFuse nominated 245 chimeras while confirming 70% of the true positives. Overall, these results suggest that ChimeraScan is among the more stringent programs while enriching for true positives.
CONCLUSION
Here, we present an optimized publicly available chimera discovery methodology for identifying novel therapeutically targetable gene fusions in human cancers. Our results suggest that ChimeraScan produces a stringent list of predictions that are enriched with true positives. Furthermore, due to its trimmed alignment steps we believe ChimeraScan will be scalable when longer reads are available to provide increased coverage of fusion junctions. Overall, we feel that with the existing features ChimeraScan is a user-friendly tool that will enable other research groups to make discoveries within their own RNA-Seq data collections. 
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Breast cancer is a heterogeneous disease that has a wide range of molecular aberrations and clinical outcomes. Here we used paired-end transcriptome sequencing to explore the landscape of gene fusions in a panel of breast cancer cell lines and tissues. We observed that individual breast cancers have a variety of expressed gene fusions. We identified two classes of recurrent gene rearrangements involving genes encoding microtubule-associated serine-threonine kinase (MAST) and members of the Notch family. Both MAST and Notch-family gene fusions have substantial phenotypic effects in breast epithelial cells. Breast cancer cell lines harboring Notch gene rearrangements are uniquely sensitive to inhibition of Notch signaling, and overexpression of MAST1 or MAST2 gene fusions has a proliferative effect both in vitro and in vivo. These findings show that recurrent gene rearrangements have key roles in subsets of carcinomas and suggest that transcriptome sequencing could identify individuals with rare, targetable gene fusions.
Recurrent gene fusions and translocations have long been associated with hematologic malignancies and rare soft-tissue tumors as being 'driving' genetic lesions [1] [2] [3] . Over the last few years, it has become apparent that these genetic rearrangements are also present in common solid tumors, including a large subset of prostate cancers 4, 5 and smaller subsets of lung cancer, among other types of tumors 6 . Secretory breast cancer, a rare subtype of breast cancer, is characterized by recurrent gene fusions of ETV6 and NTRK3 (ref. 7) . Although multiple breast cancer genomes have been sequenced 8, 9 , and complex somatic rearrangements have been observed 10 , the driving recurrent gene fusions have not been identified.
We used paired-end transcriptome sequencing on a panel of 89 breast cancer cell lines and tumors (Supplementary Fig. 1 ) and then applied our previously developed chimera discovery pipeline 11, 12 . This panel represented a spectrum of breast carcinoma and included 42 estrogen receptor (ER)-positive, 21 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (ERBB2)-positive and 27 triple negative (ER − , progesterone receptor-negative (PR − ) and ERBB2 − ) samples (Supplementary Table 1 ). Investigation of fusion transcripts led to the identification of 384 expressed gene fusions at an average of nearly five fusions per breast cancer sample, with a slightly higher number of gene fusions in the cell lines compared to the primary tumors ( Supplementary  Fig. 1b and Supplementary Table 2) . Notably, we found that only SEC16A-NOTCH1 was recurrent in our compendium, even though several fusion genes appeared in combination with different fusion partners. Overall, we found 24 genes to be recurrent fusion partners (Supplementary Table 2 ). To focus on potentially tumorigenic driver fusions, we prioritized the gene fusions based on the known cancerassociated functions of component genes. Although there were many singleton fusions in our compendium that met these criteria, we identified five instances of fusions of MAST family kinases and eight instances of fusions of genes in the Notch family ( Fig. 1 and  Supplementary Fig. 2) .
The genes encoding members of the MAST kinase family are characterized by the presence of a serine-threonine kinase domain, a second 3 MAST domain with some similarity to kinase domains and a PDZ domain 13 . Little is known about the biological role of MAST kinases, and somatic alterations have not previously been described in cancer. Initially, we identified three independent instances of MAST gene fusions using transcriptome analyses: fusions of ARID1A and MAST2, ZNF700 and MAST1, and NFIX and MAST1 (Fig. 1a) . We devised a targeted sequencing approach to screen additional samples for MAST gene fusions. We generated and captured a transcriptome library of 74 pooled breast carcinoma RNAs with baits encompassing 
ZNF700 MAST1
Chr. ( e x o n s 2 -2 8 ) MAST1 and MAST2. After sequencing, we discovered two new MAST gene fusions: TADA2A-MAST1 and GPBP1L1-MAST2 (Fig. 1a) . The samples with MAST gene fusions are distinct from those with Notch family gene fusions (Fig. 1b) .
We investigated the function of the MAST fusions (Fig. 2) and confirmed the fusions using fusion-specific PCR (Fig. 2a) . All five MAST fusions encoded contiguous open reading frames (ORFs), some of which retained the canonical serine-threonine kinase domain and all of which retained the PDZ domain and the 3 kinase-like domain (Fig. 2b) . Therefore, in total, we discovered five new gene fusions encoding MAST1 and MAST2 in a cohort of approximately 100 breast cancer samples and more than 40 cell lines, suggesting that the newly identified MAST gene fusions are present in a subset of 3-5% of breast cancers.
The ZNF700-MAST1 fusion transcript encodes a truncated MAST1 protein that retains the 3 kinase-like and PDZ domains. We cloned the ORF of the ZNF700-MAST1 fusion gene to test its phenotypic effects and used a full-length MAST2 expression construct to mimic the function of ARID1A-MAST2 overexpression. To assess the potential oncogenic functions of genes encoding MAST, we ectopically overexpressed epitopetagged truncated MAST1 and full-length MAST2 in the benign breast cell line TERT-HME1 (Supplementary Fig. 3a-h) . We then cloned and expressed all five MAST1 and MAST2 fusions. Consistent with the earlier observations, TERT-HME1 cells overexpressing the five MAST fusions (Fig. 2c) had greater cell proliferation (Fig. 2e) . Overall, these results suggest that ectopic expression of the MAST fusions results in growth and a proliferative advantage in benign breast epithelial cells. Because the endogenous ARID1A-MAST2 fusion is present in the breast cancer cell line MDA-MB-468, we used multiple independent siRNAs specific to MAST2 or the ARID1A-MAST2 fusion to achieve knockdown of the ARID1A-MAST2 fusion protein ( Supplementary  Fig. 3i-s) . Knockdown of MAST2 showed significant inhibitory effects on growth in MDA-MB-468 cells but not in the fusion-negative cell line BT-483 or in benign TERT-HME1 breast cells (Fig. 2d) . To further characterize the effects of the ARID1A-MAST2 fusion in MDA-MB-468 cells, we used shRNA targeting MAST2, which showed efficient knockdown of ARID1A-MAST2 fusion transcript and protein (Supplementary Fig. 3k,l) . MDA-MB-468 cells treated with MAST2 shRNA had a reduction in growth, as shown in a colony formation assay (Fig. 2f) , and showed increased apoptosis and S-phase arrest (Supplementary Fig. 3m,n) . In the mouse xenograft model, MDA-MB-468 cells transiently transfected with MAST2 shRNA did not establish palpable tumors over a time course of 4 weeks after transfection (Fig. 2g) . Our knockdown studies showed that the ARID1A-MAST2 fusion is a key driver fusion in MDA-MB-468 cells.
In addition to MAST fusions, we found a total of eight rearrangements involving either NOTCH1 or NOTCH2 (Fig. 1b  and Supplementary Fig. 2) . We found all of these rearrangements in ER − breast carcinomas (P = 0.008) and all but one rearrangement in triple-negative breast carcinomas. We focused on one ER − tumor and three ER − breast cancer cell lines with 3 NOTCH1 or NOTCH2 fusion transcripts in our functional studies. The Notch fusion transcripts were abundantly expressed and were specific to the samples with DNA rearrangements (Fig. 3a) .
All the fusion transcripts retained the exons that encode the Notch intracellular domain (NICD), which is responsible for inducing the transcriptional program following Notch activation (Fig. 3b) . We characterized the DNA breakpoints associated with Notch fusions by mate-pair genomic library sequencing or by long-range genomic PCR ( Supplementary Fig. 4a,b) . We categorized the predicted ORFs for the NOTCH1 and NOTCH2 fusion transcripts into two classes (Fig. 3b) . For both the SEC16A-NOTCH1 fusions and the intragenic NOTCH1 fusion in the HCC1599 cell line, the predicted ORFs initiated after the S2 cleavage site but before the S3 -secretase cleavage site, similar to that seen in the TCRB-NOTCH1 fusion in the adult lymphocytic leukemia T cell line CUTLL1 (ref. 14) . In contrast, we predicted the SEC22B-NOTCH2 fusion ORF to initiate just after the -secretase S3 cleavage site. The resulting protein would be nearly identical to NICD, and we predict that it would be highly active and independent of cleavage by -secretase (Fig. 3b) .
We saw substantially higher Notch responsive transcriptional activity in the three cell lines with Notch fusions compared to the other breast cell lines using a Notch luciferase reporter (Fig. 3c) . Therefore, each of the three Notch fusions is capable of activating the expression of Notch-responsive genes. Using an antibody specific to the -secretase cleaved active form of the NOTCH1 NICD, both HCC1599 and HCC2218 showed high concentrations of NICD, consistent with the fusion protein acting as a substrate for activation by -secretase (Fig. 3d) . The HCC1187 cell line, which has a NOTCH2 fusion gene, contains little NOTCH1 NICD. Most breast cancer lines express wildtype NOTCH1 (Fig. 3d, middle) ; however, only the two cell lines with NOTCH1 fusion alleles showed high concentrations of activated NICD. Each of the three fusion alleles, which we co-transfected with a Notch reporter plasmid, induced Notch-responsive transcription that was equivalent to NICD (Fig. 3e) . The three breast cell lines containing the Notch fusions showed decreased cell-matrix adhesion and grew in suspension or as weakly adherent clusters, which was in contrast to the majority of breast carcinoma cell lines. When we transduced NOTCH1 and NOTCH2 fusion alleles to create stable pools of TERT-HME1 cells, we observed notable morphological changes (Fig. 3f) . TERT-HME1 cells had adherent epithelial properties, whereas cells expressing Notch fusion lost adherence and propagated as weakly attached clusters, similar to the index lines with Notch fusions and consistent with the previously reported effects of NICD expression in MCF10A cells 15 . Furthermore, the fusion alleles markedly induced expression of the Notch target genes MYC, HES1 and HEY1 (Fig. 3g) .
The Notch fusions represent two functional classes with respect to dependence on the activity of -secretase. Fusions in BrCa10040, HCC2218 and HCC1599 cells are dependent on S3 cleavage for activity and are sensitive to -secretase inhibitors (GSIs). The fusion class in HCC1187 cells is independent of S3 cleavage. We established stable Notch reporter lines from each of the three Notch fusion index lines and treated them with the -secretase inhibitor N-[(3,5-difluorophenyl)acetyl]-L-al anyl-2-phenyl]glycine-1,1-dimethylethyl ester (DAPT) 16 . We saw a reduction of Notch reporter activity after treatment with DAPT in the HCC1599 and HCC2218 fusion alleles (Fig. 4a) . However, Notch reporter activity was only slightly diminished by treatment with DAPT in HCC1187 cells, which express a -secretase-independent Notch fusion allele that is capable of activating Notch reporter activity. DAPT treatment also substantially reduced NICD protein concentrations in both of the -secretase inhibitor-sensitive cell lines (Fig. 4b) . Furthermore, the index cell lines showed dependence on Notch signaling for proliferation and survival ( Fig. 4c) . The HCC1599 and HCC2218 cell lines showed marked reductions in proliferation after treatment with DAPT. The HCC1187 cell line, which expresses GSI-independent NOTCH2 fusion, had no reduction in proliferation after DAPT treatment, which is also the case in breast cell lines not expressing Notch fusion alleles. Treatment with DAPT repressed the expression of the Notch targets MYC and CCND1 (Fig. 4d) , two genes that have a key role in mouse mammary tumorigenesis induced by Notch 17, 18 , which further supports the idea GSIs could be useful in treating cancers that have activated Notch alleles. Consistent with this, treatment with DAPT significantly reduced tumor volume in a xenograft tumor model of HCC1599 cells (Fig. 4e) .
Since the discovery of the TMPRSS2-ERG gene fusion in approximately 50% of prostate cancers, emerging evidence has suggested that recurrent gene fusions have a more substantial role in common solid tumors than was previously known. The MAST and Notch aberrations in breast cancer are new classes of rare but functionally recurrent gene fusions with therapeutic implications (similar to the anaplastic lymphoma receptor tyrosine kinase (ALK) fusions in lung cancer). MAST kinase and Notch gene rearrangements were mutually exclusive aberrations in the samples we tested, and, together, may be present in up to 5-7% of breast cancers. The discovery of functionally recurrent MAST and Notch fusions in a subset of breast carcinomas is a promising path for future research and treatment in breast cancer and illustrates the power of next-generation sequencing as a tool in the development of personalized medicine.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
